Details of the Drug

General Information of Drug (ID: DMB4SFH)

• Drug Name: Mepyramine
• Synonyms: Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine

Indication

Disease Entry	ICD 11	Status	REF
Allergy	4A80-4A85	Approved	[1], [2]

• Therapeutic Class: Antiasthmatic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 285.4
  Topological Polar Surface Area (xlogp); 3.3
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• Chemical Identifiers:
  Formula: C17H23N3O
  IUPAC Name: N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
  Canonical SMILES: CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
  InChI: InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3
  InChIKey: YECBIJXISLIIDS-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4992
  ChEBI ID: CHEBI:6762
  CAS Number: 91-84-9
  DrugBank ID: DB06691
  TTD ID: D08JZS
  VARIDT ID: DR00564

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[2], [3], [4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation/carnitine transporter 2 (SLC22A5)	DT3HUVD	S22A5_HUMAN	Substrate	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Allergy
• ICD Disease Classification: 4A80-4A85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
Organic cation/carnitine transporter 2 (SLC22A5)	DTP	OCTN2	9.94E-01	1.54E-02	6.61E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mepyramine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Mepyramine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]

Coadministration of a Drug Treating the Disease Different from Mepyramine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Mepyramine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[23]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Mepyramine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[23]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Mepyramine and OPC-34712.	Depression [6A70-6A7Z]	[22]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Mepyramine and Esketamine.	Depression [6A70-6A7Z]	[24]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Mepyramine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[22]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Mepyramine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[25]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Mepyramine and Lasmiditan.	Migraine [8A80]	[24]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Mepyramine and Methylscopolamine.	Peptic ulcer [DA61]	[22]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Mepyramine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[22]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1220).
• [2] Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.
• [3] Receptor mediation and nociceptin inhibition of bradykinin-induced plasma extravasation in the knee joint of the rat. Inflamm Res. 2009 Dec;58(12):873-80.
• [4] Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7.
• [5] Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
• [6] Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
• [7] Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
• [8] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [9] Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
• [10] Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
• [11] Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
• [12] Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
• [13] Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
• [14] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [15] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [16] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [17] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [18] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [19] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [20] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [21] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
• [22] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [23] Product Information. Anoro Ellipta (umeclidinium-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
• [24] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.